Evidence map›Paper›PMID 41731921›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

A Renal Clearable Probe for In Vivo Monoamine Oxidase (MAO) Detection.

Marcia Domínguez, David Azorín-Soriano, Araceli Lérida-Viso, Jessie García-Fleitas, Paula M Soriano-Teruel, Jennifer Soler Beatty, Paula Rodrigo-Martínez, Pau Arroyo, Sara Rojas-Vázquez, Isabel Fariñas and 4 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Marcia DomínguezInstituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València, Universitat de València, Valencia, Spain.
David Azorín-SorianoInstituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València, Universitat de València, Valencia, Spain.
Araceli Lérida-VisoInstituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València, Universitat de València, Valencia, Spain.
Jessie García-FleitasInstituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València, Universitat de València, Valencia, Spain.
Paula M Soriano-TeruelInstituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València, Universitat de València, Valencia, Spain.
Jennifer Soler BeattyInstituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València, Universitat de València, Valencia, Spain.
Paula Rodrigo-MartínezInstituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico, Universitat de València, Universitat Politècnica de València, Burjassot, Valencia, Spain.
Pau ArroyoInstituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico, Universitat de València, Universitat Politècnica de València, Burjassot, Valencia, Spain.
Sara Rojas-VázquezInstituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València, Universitat de València, Valencia, Spain.
Isabel FariñasInstituto de Biotecnología y Biomedicina (BIOTECMED), Universitat de València, Valencia, Spain.
Félix SancenónInstituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València, Universitat de València, Valencia, Spain.
Juan F BlandezInstituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València, Universitat de València, Valencia, Spain.
Alba García-FernándezInstituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València, Universitat de València, Valencia, Spain.
Ramón Martínez-MáñezInstituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València, Universitat de València, Valencia, Spain.ORCID https://orcid.org/0000-0001-5873-9674

Funding

CIACIF from GVA (CIACIF/2022/132CIBER-Consorcio Centro de Investigación Biomédica en Red CB06/01/2012CIBER-Consorcio Centro de Investigación Biomédica en Red CB06/05/0086European Regional Development Fund-A way of doing Europe CIPROM/2021/007Generalitat Valenciana (GVA) PID2020-117937GB-I00GRISOLIA from GVA GRISOLIAP/2021/122Instituto de Salud Carlos III and the European Social Fund for "Miguel Servet" (CP25/00067)la Caixa" Foundation ID 100010434LCF/BQ/PR24/12050022Universitat Politècnica de València
6 · The paper itself

Abstract

Hyperactivation of monoamine oxidase enzymes (MAO) is associated with uncontrolled production of neurotoxic compounds such as reactive oxygen species, whose accumulation is linked to neurodegenerative, chronic, and age-related diseases. Although chromo-fluorogenic probes for detecting and quantifying MAO activity have been reported, non-invasive methods for monitoring MAO overexpression in vivo remain elusive. Here, we report a renal-clearable fluorogenic probe based on the cyanine-7 fluorophore (Cy7-MAO) for in vivo detection of MAO overexpression through a simple measurement of the fluorescence in urine. The probe incorporates sulfonic acid moieties for renal clearance and a propylamino group as a MAO substrate. Upon administration, Cy7-MAO is hydrolysed at the site by MAO, releasing a highly emissive Cy7 fluorophore, which is excreted in urine and quantified by fluorescence. Cy7-MAO is validated in vitro using HepG2 liver human cells, which express elevated MAO levels. We further demonstrate the in vivo applicability of Cy7-MAO for MAO activity monitoring in aged mice, which show significantly higher urine fluorescence than young mice, consistent with an elevated MAO activity in older animals. These findings support Cy7-MAO as a tool for longitudinal assessment of MAO activity in vivo, providing a novel approach to study MAO-related pathologies.

Indexed as

Fluorescent DyesKidneyMonoamine OxidaseAnimalsFluorescent Chemosensor CompoundsHep G2 CellsHumansMaleMiceFluorescent Chemosensor CompoundsFluorescent DyesMonoamine Oxidasemonoamine oxidasenon‐invasive toolrenal clearable probezwitterionic compounds

Identifiers

PMID41731921
PMCPMC13104153

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.